Drug Trial Radar · NCT07066722
A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults
Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Jul 7, 2025
Primary completion
Dec 17, 2025
Study completion Dec 17, 2025
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of the study is to gather information on how the drug behaves in healthy adults, how it is absorbed, and how it interacts when taken with other medicines.
Conditions
- HIV Infections
Interventions
VH4524184Drug
VH4524184 will be administered.
ItraconazoleDrug
Itraconazole will be administered.
RifabutinDrug
Rifabutin will be administered.
PhenytoinDrug
Extended phenytoin sodium will be administered.
MetforminDrug
Metformin will be administered.
DigoxinDrug
Digoxin will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Maximum plasma concentration (Cmax) for VH4524184Time frame: Up to Day 18
- Part 1: Area under the concentration-time curve from 0 to tau (AUC0-t) for VH4524184Time frame: Up to day 18
- Part 1: Area under the concentration-time curve from 0 to infinity (AUC0-inf) for VH4524184Time frame: Up to day 18
- Part 2: Cmax for VH4524184Time frame: At Day 1, Day 14, Day 19 and Day 22
- Part 2: AUC0-t of VH4524184Time frame: At Day 1, Day 14, Day 19 and Day 22
- Part 2: AUC0-inf of VH4524184Time frame: At Day 1, Day 14, Day 19 and Day 22
- Part 2: Cmax for metforminTime frame: At Day 1 and Day 15
- Part 2: AUC0-t for metforminTime frame: At Day 1 and Day 15
- Part 2: Cmax for DigoxinTime frame: At Day 1 and Day 15
- Part 2: AUC0-t for DigoxinTime frame: At Day 1 and Day 15
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Lenexa, Kansas
GSK Investigational Site
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.